Table 1 Characteristics of patients with newly diagnosed T1D in the 2020–2022 cohort versus the 2017–2019 cohort

Newly diagnosed T1D patients

88

76

-

Age of onset (years), median (IQR)

7.0 (3.5,10.0)

6.050 (3.8,10.0)

0.842

Male sex, n (%)

45 (51.14)

40 (52.63)

0.848

Height (cm)

124.60 ± 25.41

124.88 ± 19.16

0.956

Height Z-score

0.49 ± 1.26

0.16 ± 1.47

0.261

Weight (kg)

22.00 (15.0,29.5)

21.00 (16.0,30.8)

0.915

Weight Z-score

-0.030(-0.9,0.8)

-0.205(-0.9,0.5)

0.439

BMI (kg/m²)

15.86 ± 1.99

15.29 ± 1.70

0.173

BMI Z-score

-0.25 ± 1.23

-0.43 ± 1.06

0.483

COVID-19 Nucleic acid detection

Negative

-

-

Random glucose level (mmol/L)

28.80 (22.1,32.1)

28.350 (21.9,33.3)

0.456

Fasting insulin level (uIU/ml)

1.60 (1.2,2.8)

1.60 (1.2,2.1)

0.587

Fasting C-peptide (ng/ml)

0.28 (0.2,0.4)

0.34 (0.2,0.6)

0.156

HbA1c (%)

12.57 ± 2.35

12.43 ± 2.14

0.691

DKA on presentation n (%)

53 (60.23)

42 (55.26)

0.521

Diabetes-Associated Auto-antibodies (one or more antibody positive), n (%)

49 (55.68)

35 (46.05)

0.219

Anti-GAD65 n (%)

43 (48.86)

26 (34.21)

0.058

IAA n (%)

19 (21.59)

15 (19.74)

0.770

Treatments (Intensive insulin therapy/Insulin pump therapy)

54/34

48/28

-